A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

Gilead ...

【吉利德中国回应裁员：正在进一步调整资源 为长效HIV新药等近期 上市 的产品做准备】2024年年底至2025年3月，跨国药企 吉利德科学 （ Gilead Sciences ）分别在西雅图办事处、 加州 总部进行裁员，并宣布2025年中结束运营其细胞治疗子公司Kite Pharma在 费城 的工厂。日前， 吉利德 ...

ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

While Gilead is eliminating 149 positions at its headquarters in Foster City, Roche is letting go of 108 workers at its ...

Gilead Sciences recently experienced a significant ... highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Gilead Sciences. “Once-yearly lenacapavir, if approved, could become an important new HIV prevention option that could help address PrEP adherence and persistence challenges for individuals who ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...